ASCO 2011
Exemestane Significantly Reduces Risk of Invasive, Preinvasive Breast Cancers in Postmenopausal Women at High Risk
Exemestane, an aromatase inhibitor, can be considered a new option for primary prevention of breast cancer in postmenopausal women, results of a randomized, placebo-controlled trial reported upon during the American Society of Clinical Oncology's 2011 Annual Meeting and published online in The New England Journal of Medicine have found.
